Lexington biotech plots $86M IPO as key gene therapy trial nears
September 01, 2017 at 11:22 AM EDT
Nightstar Therapeutics, which has a small headquarters in London and a larger office in Massachusetts, is gearing up for a late-stage study of a rare eye disease drug.
